Patents Assigned to Cell Signaling Technology
  • Patent number: 9453845
    Abstract: The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partne
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 27, 2016
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Albrecht Moritz, John Edward Rush, II, Roberto Polakiewicz
  • Publication number: 20160215353
    Abstract: In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of CD74 with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The CD74-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Application
    Filed: April 12, 2016
    Publication date: July 28, 2016
    Applicant: Cell Signaling Technology, Inc.
    Inventors: Ting-Lei Gu, Ailan Guo
  • Patent number: 9364477
    Abstract: The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: June 14, 2016
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Ting-Lei Gu, Meghan Ann Tucker, Herbert Haack, Katherine Eleanor Crosby, Victoria McGuinness Rimkunas
  • Patent number: 9328349
    Abstract: In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of CD74 with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The CD74-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: May 3, 2016
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Ting-Lei Gu, Ailan Guo
  • Patent number: 9249231
    Abstract: There is provided a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) at least one sumoylated lysine residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said sumoylated lysine residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs. Also provided is a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) a C-terminal aspartic acid residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said C-terminal aspartic acid residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 2, 2016
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Michael Comb, Ailan Guo, John Edward Rush, II, Jun-Ming Cai, Jing Li, Jing Zhou
  • Patent number: 9239331
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: January 19, 2016
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 9181326
    Abstract: The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: November 10, 2015
    Assignee: Cell Signaling Technology, Inc.
    Inventors: John Edward Rush, II, Jing Li, Ailan Guo
  • Patent number: 9102713
    Abstract: The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: August 11, 2015
    Assignee: Cell Signaling Technology, Inc.
    Inventors: John Edward Rush, II, Jing Li, Ailan Guo
  • Patent number: 9085609
    Abstract: A method is provided for producing motif-specific, context-independent antibodies that recognize a plurality of peptides or proteins within a genome that contain the same post-translationally modified motif. The method includes the step of immunizing a host with a degenerate peptide library antigen featuring (i) a fixed target motif containing one or more invariant amino acids including at least one modified amino acid, and (ii) a plurality of degenerate amino acids flanking the motif. Motif-specific, context-independent antibodies produced by the disclosed method are also provided. The method encompasses motifs consisting of a single modified amino acid, as well as short motifs comprising multiple invariant amino acids including one or more modified amino acids, such as all or part of kinase consensus substrate motifs, protein-protein binding motifs, or other cell signaling motifs. Methods of using the antibodies, e.g. for genome-wide profiling, are also provided.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: July 21, 2015
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Michael J. Comb, Peter Hornbeck, Patrick Li
  • Patent number: 8956822
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: February 17, 2015
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Publication number: 20140134640
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Application
    Filed: July 12, 2013
    Publication date: May 15, 2014
    Applicant: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 8618260
    Abstract: The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.
    Type: Grant
    Filed: September 8, 2007
    Date of Patent: December 31, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Peter Hornbeck, Albrecht Moritz, John Rush, Steven Gygi
  • Publication number: 20130302829
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 14, 2013
    Applicants: Cell Signaling Technology, Inc., Ventana Medical Systems, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Publication number: 20130245237
    Abstract: The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.
    Type: Application
    Filed: April 4, 2013
    Publication date: September 19, 2013
    Applicant: Cell Signaling Technology, Inc.
    Inventors: John Edward Rush, II, Jing Li, Ailan Guo
  • Patent number: 8512967
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: August 20, 2013
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Patent number: 8486645
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: July 16, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 8481279
    Abstract: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: July 9, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 8466160
    Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: June 18, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Roberto Polakiewicz, Ailan Guo, Katherine Eleanor Crosby, Qingfu Zeng, Kimberly A Lee
  • Patent number: 8383799
    Abstract: In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: February 26, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Ailan Guo, Anthony Possemato
  • Patent number: 8377642
    Abstract: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: February 19, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu